Repeated Tolerance Testing Made a THC Avoidance Effect Appear More Persistent in Rats

A 1977 rat study found that repeated testing changed how long THC tolerance appeared to persist. Separate groups tested after abstinence and repeatedly challenged animals did not provide the same timeline.

Pretreatment outside the task had limited persistence

A multiday THC regimen given independently of testing reduced later conditioned-avoidance impairment at short intervals but not at the longer fourteen-day comparison. A single independent exposure did not produce the same later protection. Exposure amount and timing both mattered.

Retesting introduced additional experience and drug exposure

When the same rats underwent repeated tolerance tests, reduced impairment appeared to persist for weeks. Those tests were not passive observations: they involved renewed drug-state task experience. Their result therefore could not be interpreted as an undisturbed measure of how long an earlier adaptation lasted.

Tolerance can have multiple contributors

The authors discussed metabolic, functional and compensatory behavioral explanations. The design does not assign a precise share to each. It does show why a duration claim must describe whether animals were challenged repeatedly or left untested until the final time point.

The study is useful for evaluating tolerance-break claims based on repeated assessment. Testing can alter the exposure history being measured. It does not establish a human abstinence interval or show that practiced performance eliminates all cannabis effects across unfamiliar tasks.

Related: interpreting cannabis tolerance claims.

Research cited

Larsen FF; Pryor GT. Factors influencing tolerance to the effects of delta9-THC on a conditioned avoidance response. Pharmacology, biochemistry, and behavior (1977). doi:10.1016/0091-3057(77)90228-3. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

A review published in 2020 graded psychiatric evidence from studies of CBD and CBD-containing nabiximols. Its recommendation labels should not be quoted as though every underlying intervention was purified CBD or every study was randomized. The included designs ranged widely The review identified 23 relevant studies spanning case reports, case…

Spread the love

Read Article: A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

A 2021 ocular CBD review brought together in-vitro and in-vivo research, proposed molecular targets and possible therapeutic applications. This evidence maps a development pathway; it does not establish that CBD products are effective eye treatments. The experimental system belongs in the conclusion A cellular result can identify a target or…

Spread the love

Read Article: CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

A 2021 review evaluated CBD research on reinforcing, motivational and withdrawal-related drug effects. These outcomes can inform substance-use-disorder research, but an improvement in one cannot establish successful treatment across all of them. The source combined preclinical and clinical reports The review covered alcohol, opioids, cannabinoids, nicotine and psychostimulants. An animal…

Spread the love

Read Article: CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us